Article
Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09).
Prostate cancer and prostatic diseases - 1 Jun 2015
Joerger M, van Schaik R H N, Becker M L, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C
Abstract excerpt
BACKGROUND: This study was initiated to explore the impact of organic cation transporter 1 (OCT1) and multidrug and toxin extrusion transporter 1 (MATE1) genetic polymorphisms on toxicity, and clinical activity of metformin in patients with castration-resistant prostate cancer (CRPC). METHODS: The SAKK 08/09 trial included 44 patients with CRPC to receive single-agent metformin 1000 mg two times a day until...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.